We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.05 | 1.52% | 3.35 | 3.30 | 3.40 | 3.35 | 3.30 | 3.30 | 164,059 | 15:18:31 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -2.37M | -0.0262 | -1.28 | 3.02M |
From Apr 2019 to Apr 2024
TIDMVAL
RNS Number : 5388Z
ValiRx PLC
15 March 2017
ValiRx Plc
("ValiRx" or "the Company")
PDMR / Director Dealing
London, UK., 15 March 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received the following notifications from PDMRs of dealings in the Company's shares, all of which related to the issue of shares announced on 2 March 2017 for which Admission to trading on AIM occurred on 15 March 2017.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Hot Features
Premium
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ----------------------------------------------------------------------------------
a) Name Satu Vainikka
---- -------------------------------------- ------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
---- -------------------------------------- ------------------------------------------
b) Initial notification/ Initial Notification
Amendment
---- -------------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ----------------------------------------------------------------------------------
a) Name ValiRx Plc
---- -------------------------------------- ------------------------------------------
b) LEI N/A
---- -------------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------
a) Description of the
financial instrument,
type of instrument
----
Identification code GB00BWWYSP41
b) Nature of the transactions Issue of Ordinary Shares
---- -------------------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------------------- --------------------------- ----------
2.50 p 400,000
--------------------------- ----------
d) Aggregated information
----
- Aggregated volume 400,000
- Price 2.50 p
-------------------------------------- -----------------------------------------------
e) Date of the transaction 15 March 2017
---- -------------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
---- -------------------------------------- ------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ----------------------------------------------------------------------------------
a) Name George Morris
---- -------------------------------------- ------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------
a) Position/status Chief Operating Officer
---- -------------------------------------- ------------------------------------------
b) Initial notification/ Initial Notification
Amendment
---- -------------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ----------------------------------------------------------------------------------
a) Name ValiRx Plc
---- -------------------------------------- ------------------------------------------
b) LEI N/A
---- -------------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------
a) Description of the
financial instrument,
type of instrument
----
Identification code GB00BWWYSP41
b) Nature of the transactions Issue of Ordinary Shares
---- -------------------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------------------- --------------------------- ----------
2.50 p 400,000
--------------------------- ----------
d) Aggregated information
----
- Aggregated volume 400,000
- Price 2.50 p
-------------------------------------- -----------------------------------------------
e) Date of the transaction 15 March 2017
---- -------------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
---- -------------------------------------- ------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ----------------------------------------------------------------------------------
a) Name Gerry Desler
---- -------------------------------------- ------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------
a) Position/status Finance Director
---- -------------------------------------- ------------------------------------------
b) Initial notification/ Initial Notification
Amendment
---- -------------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ----------------------------------------------------------------------------------
a) Name ValiRx Plc
---- -------------------------------------- ------------------------------------------
b) LEI N/A
---- -------------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------
a) Description of the
financial instrument,
type of instrument
----
Identification code GB00BWWYSP41
b) Nature of the transactions Issue of Ordinary Shares
---- -------------------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------------------- --------------------------- ----------
2.50 p 400,000
--------------------------- ----------
d) Aggregated information
----
- Aggregated volume 400,000
- Price 2.50 p
-------------------------------------- -----------------------------------------------
e) Date of the transaction 15 March 2017
---- -------------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
---- -------------------------------------- ------------------------------------------
***S ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Tel: +44 (0) 7736
Manager 564 686
mark.treharne@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20
(Nominated Adviser) 7213 0880
Liam Murray / Jo Turner
Beaufort Securities Limited Tel: +44 (0) 207
(Joint Broker) 382 8300
Jon Belliss
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGCGDXIDBBGRU
(END) Dow Jones Newswires
March 15, 2017 05:33 ET (09:33 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
